Science Explorer Back to mapMap
Discussion
Topic · Oncology

CAR-T cell therapy research

CAR-T cell therapy research is a research topic within Oncology. Science Explorer counts 48k research works in it since 1950. 10.1% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on Chimeric Antigen Receptor (CAR) T cell therapy, a form of immunotherapy that uses genetically engineered T cells to target and destroy cancer cells. The papers cover various aspects of CAR T cell therapy, including its application in treating leukemia, lymphoma, and solid tumors, the management of cytokine release syndrome associated with this therapy, and the long-term efficacy and safety of CAR T cell treatment.

  • CAR T Cells
  • Chimeric Antigen Receptor
  • T Cell Therapy
  • Leukemia
  • Lymphoma
  • Immunotherapy
  • Cytokine Release Syndrome
  • Tumor Regression
  • Adoptive Cell Transfer
  • Cancer Immunotherapy
Research works
48k
fractional, since 1950
In the world top 10%
4.9k
per year above
Top-10% rate
10.1%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+53%
the tick is no change
Largest producer
United States
49% of the 10 largest, 2022-now
CAR-T cell therapy research

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead CAR-T cell therapy research research?

By volume, the United States and China publish the most (7.2k and 3k works in 2022-now).

By volume, 2022-now

  1. 1 United States 7.2k works
  2. 2 China 3k works
  3. 3 Germany 960 works
  4. 4 United Kingdom 633 works
  5. 5 Japan 571 works
  6. 6 France 551 works
  7. 7 Italy 526 works
  8. 8 Spain 448 works
  9. 9 Canada 362 works
  10. 10 India 352 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 49.0%China: 20.8%Germany: 6.6%United Kingdom: 4.3%6 others listed: 19.2%49%largest
United States7,168 · 49.0%China3,047 · 20.8%Germany960 · 6.6%United Kingdom633 · 4.3%6 others listed2,811 · 19.2%

Shares of the rows listed above, not of the whole node.

Which institutions lead CAR-T cell therapy research research?

By volume in 2022-now, Harvard University publishes the most CAR-T cell therapy research research, followed by The University of Texas MD Anderson Cancer Center and National Institutes of Health.

By volume, 2022-now

  1. 1 Harvard UniversityUnited States 364 works
  2. 2 The University of Texas MD Anderson Cancer CenterUnited States 276 works
  3. 3 National Institutes of HealthUnited States 196 works
  4. 4 University of PennsylvaniaUnited States 189 works
  5. 5 Mayo ClinicUnited States 167 works
  6. 6 Memorial Sloan Kettering Cancer CenterUnited States 159 works
  7. 7 Stanford UniversityUnited States 131 works
  8. 8 Moffitt Cancer CenterUnited States 126 works
  9. 9 Zhejiang UniversityChina 126 works
  10. 10 Huazhong University of Science and TechnologyChina 122 works

Who are the leading researchers in CAR-T cell therapy research?

The most-cited researchers publishing on CAR-T cell therapy research include Eric S. Lander, Stacey L. Gabriel and Robert John Tibshirani.

  1. 1 Eric S. Lander United States 524k citations
  2. 2 Stacey L. Gabriel United States 402k citations
  3. 3 Robert John Tibshirani United States 396k citations
  4. 4 Guido Kroemer France 386k citations
  5. 5 Bert Vogelstein United States 373k citations
  6. 6 Gad A. Getz United States 364k citations
  7. 7 Elaine R. Mardis United States 346k citations
  8. 8 Shizuo Akira Japan 342k citations
  9. 9 Jun Wang China 340k citations
  10. 10 Giuseppe Remuzzi Italy 328k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in CAR-T cell therapy research?

The most cited paper in CAR-T cell therapy research is "PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer" (Andreas Daniel Hartkopf, Florin‐Andrei Taran, Markus Wallwiener et al., 2016), with 30,915 citations. Next come "The blockade of immune checkpoints in cancer immunotherapy" (14,033) and "Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer" (12,842).

Most cited papers
#PaperReleasedCitations
1 PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer Andreas Daniel Hartkopf, Florin‐Andrei Taran, Markus Wallwiener et al. · Breast Care Open access 2016 30,915
2 The blockade of immune checkpoints in cancer immunotherapy Drew M. Pardoll · Nature reviews. Cancer ReviewOpen access 22 Mar 2012 14,033
3 Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer Suzanne Louise Topalian et al. · New England Journal of Medicine Open access 14 Jun 2012 12,842
4 Control of Regulatory T Cell Development by the Transcription Factor Foxp3 Shohei Hori, Takashi Nomura, Shimon Sakaguchi · Science 13 Feb 2003 8,213
5 Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer Julie Renee Brahmer et al. · New England Journal of Medicine Open access 14 Jun 2012 8,100
All 100 most cited papers, with filters and sorting

Where is CAR-T cell therapy research research done?

The largest centres of CAR-T cell therapy research research in 2022-now are Beijing (China), New York (United States), Houston (United States) and Shanghai (China). Among places with at least 20 works in it, it is an unusually large share of all research in South San Francisco, Duarte and Lancaster.

Largest cities, 2022-now

  1. 1 BeijingChina 492 works
  2. 2 New YorkUnited States 425 works
  3. 3 HoustonUnited States 398 works
  4. 4 ShanghaiChina 345 works
  5. 5 PhiladelphiaUnited States 322 works
  6. 6 BostonUnited States 303 works
  7. 7 LondonUnited Kingdom 274 works
  8. 8 ParisFrance 225 works
  9. 9 SeattleUnited States 212 works
  10. 10 GuangzhouChina 203 works

Where it is the local speciality

  1. South San FranciscoUS · 51.5 works67×
  2. DuarteUS · 60.2 works63×
  3. LancasterUS · 78.1 works57×
  4. HackensackUS · 20.1 works32×
← less than its size predicts1×more →

Location quotient: how much more of its research is in CAR-T cell therapy research than the world average.

See CAR-T cell therapy research on the map

Where is the best place to study CAR-T cell therapy research?

Among universities, judged by research, Harvard University, Kettering University and University of Pennsylvania score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%30%mean 18.04%fractional works in this field (log) →share of work in the world top 10% →Kettering UniversityUniversity of Pennsy…Harvard UniversityStanford University
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Citation excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 78.415.9%7.5×364 +33.9%
2Kettering UniversityUnited States 72.725.3%49.9×27 +193.4%
3University of PennsylvaniaUnited States 72.316.6%11.8×189 +18.9%
4Stanford UniversityUnited States 67.114.3%5.8×131 +41.2%
5Massachusetts Institute of TechnologyUnited States 66.123.6%2.3×24 +36.0%
6University of California, San FranciscoUnited States 64.715.2%7.6×82 +23.4%
7Zhejiang UniversityChina 63.516.5%3.1×126 +113.9%
8Cornell UniversityUnited States 62.613.8%4.7×94 +33.0%
9University of California, Los AngelesUnited States 62.520.2%3.8×65 +24.0%
10Oncode InstituteNetherlands 60.219.0%28.2×12 +24.1%

Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in CAR-T cell therapy research, country by country

Is CAR-T cell therapy research research growing?

Output in 2022-2025 was 53% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are CAR-T cell therapy research.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is CAR-T cell therapy research as a percentage of every work published that year, 0.072% in 2024.

still counting0.050%0.10%CAR-T cell therapy research0.079% in 202519801990200020102020

Fractional works of CAR-T cell therapy research over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%CAR-T cell therapy research9.9% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about CAR-T cell therapy research. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.